Focused Orticumab Research for Treating Inflammation in Coronary Arteries
Phase 2
Not yet recruiting
- Conditions
- Acute Coronary SyndromesCoronary Arterial Disease (CAD)InflammationHeart DiseaseMyocardial InfarctAtherosclerotic Coronary Vascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Abcentra
- Target Recruit Count
- 240
- Registration Number
- NCT06927739
A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors
Phase 2
Completed
- Conditions
- InflammationCardiometabolic SyndromePsoriasisCoronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Abcentra
- Target Recruit Count
- 77
- Registration Number
- NCT04776629
- Locations
- 🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸CCT- Research at the center for Dermatology and Plastic Surgery, Scottsdale, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath